[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Veracyte Inc (VCYT)

Veracyte Inc (VCYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,424,656
  • Shares Outstanding, K 80,391
  • Annual Sales, $ 517,150 K
  • Annual Income, $ 66,350 K
  • EBIT $ 108 M
  • EBITDA $ 126 M
  • 60-Month Beta 1.95
  • Price/Sales 6.95
  • Price/Cash Flow 30.00
  • Price/Book 2.59

Options Overview Details

View History
  • Implied Volatility 49.67% (-1.95%)
  • Historical Volatility 85.49%
  • IV Percentile 7%
  • IV Rank 7.09%
  • IV High 101.25% on 05/04/26
  • IV Low 45.74% on 08/12/26
  • Expected Move (DTE 6) 2.12 (5.13%)
  • Put/Call Vol Ratio 2.50
  • Today's Volume 378
  • Volume Avg (30-Day) 206
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 4,225
  • Open Int (30-Day) 3,315
  • Expected Range 39.13 to 43.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.28
  • Number of Estimates 3
  • High Estimate $0.31
  • Low Estimate $0.26
  • Prior Year $0.38
  • Growth Rate Est. (year over year) -26.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.00 +0.61%
on 08/14/26
60.82 -32.18%
on 07/16/26
-15.37 (-27.15%)
since 07/14/26
3-Month
37.72 +9.37%
on 05/15/26
60.91 -32.28%
on 06/30/26
+2.35 (+6.04%)
since 05/14/26
52-Week
28.25 +46.02%
on 08/27/25
60.91 -32.28%
on 06/30/26
+11.21 (+37.32%)
since 08/14/25

Most Recent Stories

More News
Veracyte: Q2 Earnings Snapshot

Veracyte: Q2 Earnings Snapshot

VCYT : 41.25 (-3.17%)
Veracyte Announces Second Quarter 2026 Financial Results

Grew total revenue to  $150.3 million and testing revenue to $145.7 million , representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at...

VCYT : 41.25 (-3.17%)
Veracyte's Earnings Decline Arrives With Revenue Growth Still Intact

Barchart Research What to Expect from VCYT Earnings VCYT Generated July 29, 2026 Current Price $55.71 EPS Estimate $$0.29 Consensus Rating Moderate Buy Average Move 14.82% Veracyte's Earnings Decline Arrives...

VCYT : 41.25 (-3.17%)
Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor...

VCYT : 41.25 (-3.17%)
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July...

VCYT : 41.25 (-3.17%)
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

Genomic test using whole-transcriptome next-generation sequencing technology will be available to order on June 8 The Prosigna test predicts chemotherapy benefit and quantifies...

VCYT : 41.25 (-3.17%)
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Study provides first Level 1B evidence for genomic-guided decisions on triplet therapy in advanced disease Additional ASCO data reinforce Decipher Prostate’s utility...

VCYT : 41.25 (-3.17%)
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node involvement...

VCYT : 41.25 (-3.17%)
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from...

VCYT : 41.25 (-3.17%)
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer

Additional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized Care

VCYT : 41.25 (-3.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also...

See More

Key Turning Points

3rd Resistance Point 44.71
2nd Resistance Point 43.92
1st Resistance Point 42.58
Last Price 41.25
1st Support Level 40.46
2nd Support Level 39.67
3rd Support Level 38.33

See More

52-Week High 60.91
Fibonacci 61.8% 48.43
Fibonacci 50% 44.58
Last Price 41.25
Fibonacci 38.2% 40.73
52-Week Low 28.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.